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ABSTRACT
Expression of the transcription factor SOX4 is of-
ten elevated in human cancers, where it generally
correlates with tumor-progression and poor-disease
outcome. Reduction of SOX4 expression results
in both diminished tumor-incidence and metasta-
sis. In breast cancer, TGF--mediated induction of
SOX4 has been shown to contribute to epithelial-to-
mesenchymal transition (EMT), which controls pro-
metastatic events. Here, we identify SMAD3 as a
novel, functionally relevant SOX4 interaction part-
ner. Genome-wide analysis showed that SOX4 and
SMAD3 co-occupy a large number of genomic loci in
a cell-type specific manner. Moreover, SOX4 expres-
sion was required for TGF--mediated induction of a
subset of SMAD3/SOX4-co-bound genes regulating
migration and extracellular matrix-associated pro-
cesses, and correlating with poor-prognosis. These
findings identify SOX4 as an important SMAD3
co-factor controlling transcription of pro-metastatic
genes and context-dependent shaping of the cellular
response to TGF-. Targeted disruption of the inter-
action between these factors may have the potential
to disrupt pro-oncogenic TGF- signaling, thereby
impairing tumorigenesis.
INTRODUCTION
Increased expression of SOX4 transcription factor has been
observed in a large number of human cancers, suggest-
ing a general role in tumorigenesis (1,2). In agreement
with this notion, Sox4 hypomorphic mice have been found
to have greatly reduced spontaneous tumor-incidence (3).
Conversely, increased expression of SOX4 has been demon-
strated to promote tumor progression in both hematopoi-
etic and solid tumors (4–6).
Recently, it has become apparent that SOX4 is a key
transcriptional target of the transforming growth factor-
beta (TGF-) signaling pathway in a variety of cell-types
including T-cells, pituitary cells, breast epithelial cells and
glioma cells (7–10). The TGF- signaling pathway elicits
pleiotropic responses in cancer, acting as both a tumor-
suppressor and metastasis-promoting factor depending on
the cellular context (11). In late-stage cancers, the tumor-
suppressive component of the TGF- response is lost, al-
lowing TGF- to enhance tumor-progression by, for exam-
ple, promoting EMT (12). The metastasis promoting effects
of TGF- are regulated to a large degree by the transcrip-
tional response mediated by the receptor associated SMAD
transcription factors (SMAD2/3), which for their context-
specific target gene selection require cooperative binding
with distinct transcription factors and rely on a permissive
epigenomic state (11,13).
SOX4 is an important component in the tumor-
promoting transcriptional response induced by TGF- in
both glioma and breast cancer. In glioma, SMAD2/3 have
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been demonstrated to directly regulate the transcription of
SOX4, which was found to be essential for the maintenance
of tumor-initiating cells by promoting the SOX4-dependent
regulation of SOX2 expression (14). Recently, a number
of studies by ourselves and others have demonstrated that
SOX4 is also involved in pro-oncogenic TGF- responses
in (tumorigenic) breast epithelial cells. The transcriptional
regulation of SOX4 by TGF- is essential for the TGF-
mediated induction of EMT, a process involving the pheno-
typic conversion of epithelial cells to a mesenchymal-state
which confers pro-tumorigenic properties by inducing stem-
cell traits and promoting metastasis and therapy resistance
(5,10,15–17). Ectopic expression of SOX4 has been shown
to be sufficient to induce EMT in mammary epithelial cell
lines in vitro, which correlates with increased metastasis in
vivo (5,10,17). The EMT-promoting effects of SOX4 have
also been linked to its direct transcriptional induction of
EZH2, which is part of the polycomb-repressive complex
2 (PRC2), resulting in remodeling of the epigenome (5). Re-
cently, it has been demonstrated that SOX4 has a dichoto-
mous role downstream of TGF- in pancreatic ductal ade-
nocarcinoma (PDA) where, depending on the cellular tran-
scription factor landscape, SOX4 may mediate apoptosis or
promote oncogenesis (18). These findings indicate that co-
operativity between SOX4 and distinct transcription factors
likely shapes the SOX4-dependent transcriptional network
and cellular response.
In support of a pro-metastatic role, SOX4 has been iden-
tified in gene expression signatures mediating breast tumor
metastasis to the lung and brain (19,20).Moreover, in exper-
imental mouse models of metastasis SOX4 has been shown
to be the target of microRNA-335, which is lost during
tumor-progression thus promoting invasion, migration and
metastasis (21). Together, these findings indicate that the ex-
pression of SOX4 is likely crucial for breast cancer progres-
sion, in part by controlling TGF- mediated induction of
EMT. Despite this important role, the mechanisms through
which SOX4mediates tumor-progression remain poorly un-
derstood.
Here, by performing an unbiased transcription factor in-
teraction screen we identify SMAD3 as a novel interac-
tion partner of SOX4. We demonstrate that SOX4 specif-
ically controls a pro-oncogenic subset of SOX4/SMAD3
co-bound TGF- target genes, associated with poor-disease
outcome. Our findings thus highlight a novel role of SOX4
in the TGF- pathway by cooperatively regulating target
genes with SMAD3 in a context-dependentmanner, thereby
skewing TGF- responses.
MATERIALS AND METHODS
Cell culture and co-Immunoprecipitation assays
HEK293T,MDA-MB-231, HCC1954, MCF-7 and HMLE
cells were cultured as described previously (10,22,23). For
co-immunoprecipitation experiments HEK293T cells were
transiently transfected by overnight incubation with pre-
formed PEI:DNA complexes using 10 g of DNA and
50 g PEI. Cells were transfected with the indicated con-
structs andmatching empty vector controls. Cells were lysed
in E1A buffer (50 mM HEPES, pH 7.0, 250 mM NaCl, 5
mM EDTA and 0.1% NP-40) and subsequently immuno-
precipitation was performed using anti-HA or anti-FLAG
coupled beads (Sigma Aldrich) for 2 h at 4◦C. After three
wash steps in E1A buffer, samples were collected and boiled
for 5 min in Laemmli sample buffer. Western blot anal-
ysis was subsequently performed as described previously
(23). In order to avoid background signal from the IgG
heavy chain of the antibody used for immunoprecipitation,
HRP-conjugated FLAG (A8592, Sigma-Aldrich) and HA
(A00169-40, Genscript) antibodies were used for the detec-
tion of co-immunoprecipitated proteins. Protein expression
of whole cell lysates was assessed by using the following pri-
mary antibodies: anti-FLAG (Sigma, F7425) and anti-HA
(A00168-40, Genscript).
Generation of shRNA-based deletion of SOX4
To generate SOX4-depleted HMLE cells and respective
control, two independent pLKO.1-puro lentiviral con-
structs expressing shRNA targeting SOX4 (Sigma) or ex-
pressing shRNA control were used, respectively. Lentivirus
particles were produced by transfection of HEK293T cells
with 3.25 ug of Pax2, 1.8 g of pMD2.G and 5 g of
shRNA contracts. Twenty four hours after transfection,
medium was replaced by MEGM:DMEM/F12 media. Vi-
ral supernatants were collected 24 h after and filtered
through a 0.22mfilter and added to theHMLE cells. Cells
were selected using 1g/ml of puromycin (invivoGen). Cells
were maintained in 1 g/ml of puromycin through the cell
culture.
TF–TF interaction array
MCF7 cells were transiently transfected with FLAG-tagged
Sox4 or empty vector control. Nuclear extracts were gener-
ated 48 h after transfection. Immunoprecipitation was per-
formed using anti-FLAG coupled beads (A2220, Sigma-
Aldrich). The TF–TF-screen was performed according to
manufacturer’s protocol (Panomics). The hybridized arrays
were probed using streptavidin-HRP and were detected us-
ing ECL (GE Healthcare).
Proximity ligation assay
HMLE cells were cultured on microscope glasses (Sigma-
Aldrich) and were left untreated or treated for 16 h prior to
the assay. For the proximity ligation assay, cells were washed
once in phosphate-buffered saline (PBS) solution and fixed
using 4% paraformaldehyde in PBS for 20 min at room
temperature (RT). Subsequently, cells were washed twice in
PBS and permeabilized in PBS 0.25% triton for 5 min at
RT. Samples were washed in PBS and blocking was per-
formed in PBS containing 2% bovine serum albumin (BSA)
for 1 h at RT. Posteriorly, cells were incubated with anti-
SOX4 (Sigma-Aldrich, HPA029901) and/or anti-SMAD3
(Thermo Scientific, MA5-15663) antibodies, overnight at 4
degrees. After incubation with primary antibodies, proce-
dure was followed according to the manufacturer’s protocol
(Olink Bioscience). Accordingly, cells were washed twice in
PBS and subsequently incubated with the secondary mouse
PLUS (DUO92001, Sigma-Aldrich) and rabbit MINUS
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(Duo92005, Sigma-Aldrich) probes for 1 h at 37◦C in a dark
humidity chamber. Cells were washed three times in PBS,
followed by a ligation step for 30 min at 37◦C in a dark hu-
midity chamber (DUO92007, Sigma-Aldrich). Again, cells
were washed, followed by amplification and detection for
90 min at 37◦C in a dark humidity chamber (DUO92007,
Sigma-Aldrich). After this, cells were washed three times in
PBS and mounted in 4 ul Prolong Gold anti-fade reagent
with DAPI (Invitrogen). PLA signal was assessed by confo-
cal microscopy (Zeiss LSM 700) using the 555 nm channel.
Chromatin immunoprecipitation-sequencing (ChIP-seq)
Chromatin-immunoprecipitation was performed in
HMLE, MDA-MB-231 and HCC1954 cells using five
15 cm dishes per condition, as described previously (24).
HMLE cells were either treated with TGF- (2.5 ng/ml) for
16 h or left untreated prior to the assay. Subsequently, dou-
ble crosslinking was performed using di(N-succinimidyl)
glutarate (DSG) for 45 min followed by a 30 min incu-
bation with formaldehyde. The reaction was quenched
using incubation with 0.1 M Glycine for 5 min after
which cells were washed in PBS and nuclear extracts were
generated. Sonication using covaris was subsequently
performed for 8 min at maximum output, after which
immunoprecipitation was performed using 15 l of the
rabbit anti-SOX4 (CS-129-100, Diagenode) or 2 g of
the rabbit anti-SMAD3 (ab28379, abcam) antibodies
coupled to protein A/G sepharose beads (sc-2003, Santa
Cruz Biotechnology). Sequencing libraries were generated
using the TruSeq LT kit (Illumina) and sequencing was
performed on NextSeq platform (Illumina). Sequencing
reads were mapped to the reference genome assembly
(hg19) using Bowtie2 and peak-calling was performed
using MACS2 (default settings were used for Bowtie2 and
MACS2). Data analysis was performed using the HOMER
software package (homer.ucsd.edu/), using the functions
makeTagDirectory, findMotifsGenome.pl and annotate-
Peaks.pl (default settings and windows as indicated in the
figures. IGV was used for ChIP-seq track visualization
(25). Bedtools was used to determine the overlap between
peaksets (26). ChIP-seq experiments were performed using
two independent experimental replicates.
ChIP-qPCR
Chromatin-immunoprecipitation was performed in HMLE
cells as described above. DNA samples were amplified
using SYBR green supermix (BIO-Rad), in a white 96-
multiwell plate by LightCycler 96 system instrument
(Roche) according to the manufacture’s protocol. Ex-
pression of each gene was normalized to input and to
a negative region. All the primers for the Chip-qPCR
were designed based on the Chip-sequencing data: neg-
ative region: F-GAGCCAGGGTTTCTCTGATTC,
R-CCTCAGTGATCAGCCCTAAATG; CDH2: F-
CAGCTACTTGGGAGGCTGAG, R- GCCACTGA
AGCACATTGAAA; SPOCK1 F-TCTGTGCCACGT
GCTTACTC, R-GGCTGAGTCATGTCATGGTG;
LBH F- GATCCCTCTGGTGCTGATGT, R-
TACCTCCAGGTGGGTCAGTC; MMP10 F-
CAATGGTTGCAATTCAGACG, R- TCAGTGAG
CTGTTACCAGAAGC; NEDD9 F-CCCACCCCTAAT
TCTGAAAA, R-TCCTTTTCCTGTTCTTTCTCTTTC;
KDM7A F-AAGAGGCGGTGCTCTGTAAA, R-
GAGCTTTCAGTCTCGCCACTA.
RNA sequencing
HMLE cells were transduced using lentiviral transduction
with scrambled control or SOX4 targeting shRNA con-
structs as described previously (10). The cells were treated
with TGF- for 16 h after which RNA was isolated us-
ing the RNeasy kit (Qiagen) according to the manufac-
turer’s protocol. Purified RNA was subsequently used for
RNA-seq library preparation as described previously (24),
and sequenced on the SOLiD Wildfire sequencer (Applied
Biosystems Life Technologies). The BWApackage was used
to map sequencing reads (50 bp) to the reference genome
(hg19). The Cisgenome v2.0 package was used for quantifi-
cation of the reads, which were additionally quantile nor-
malized and log2 transformed after adding a small number
to the RPKM to avoid log-tranformation of zero values.
The RNA-sequencing was performed in duplicates for each
of the conditions tested.
Transwell migration assay
Transwell assay were performed according to the manufac-
ture’s protocol (Corning). Briefly, 30 000 scrambled con-
trol or SOX4 shRNA MDA-MB-231 cells transduced with
either an empty vector control construct or constitutively
active TGF- receptor construct were plated in the inner
compartment of the transwell plate in 300 l of medium,
with 700 l in the outer compartment. The plate was sub-
sequently incubated for 24 h at 37◦C and 5% CO2. Subse-
quently, media was removed and cells were washed, fixed
and stained with DAPI to quantify the number of migrated
cells using ImageJ software.
Survival analysis
The Molecular Taxonomy of Breast Cancer Interna-
tional Consortium (METABRIC) cohort includes DNA
copy number, whole gene expression and breast cancer-
specific survival of 1980 patients (accession number
EGAS00000000083) (27). Claudin-low subtyping was per-
formed using transcriptomic data and the predictor de-
veloped by Prat et al. (28). Signature analysis was per-
formed using the genes that were more than 0.5 log2
fold change differentially expressed between TGF--treated
or SOX4 knockdown cells and their respective controls.
Two signatures were derived: (i) overlapping regulated
genes between TGF- and SOX4 and (ii) TGF- without
SOX4-associated genes. Samples were assigned a Spearman
correlation-based score calculated between the gene expres-
sion data of each tumour and each signature. Survival was
analysed using Kaplan––Meier curves and significance as-
sessed by log-rank test. Data were analysed using R 3.2.2
and a two-sided P < 0.05 was considered significant.
Quantification of RNA expression (q-PCR)
mRNAwas extracted from cells using the Rneasy Isolation
Kit (Qiagen). According to the manufactures protocol
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for single-stranded cDNA synthesis, 500 ng of total RNA
was reverse transcribed using iScript cDNA synthesis
kit (BIO-Rad). cDNA samples were amplified using
SYBR green supermix (BIO-Rad), in a white 96 multi-
well plate by LightCycler 96 system instrument (Roche)
according to the manufacture’s protocol. To quantify
the data, the comparative Ct method was used. Relative
quantity was defined as 2-Ct and 2-Microglobulin
was used as reference gene. The following primers were
used: CDH2 F-AGTCACCGTGGTCAAACCAATCGA,
R-TGCAGTTGACTGAGGCGGGTG; SPOCK1 F-
GCTCAGATGGCCACTCCTAC, R-TCTGTGCAGG
CACTCCTTTC; LBH F-TCCCCATTCACTGCCCCG
AC, R-AAAGGCCATCCTTGCGGGGG; FERMT1
F- CTTGGTTCAGTGACAGCCCT, R-GGAGTCTA
GCCAACCTGCAT; MMP10 F-GACAGAAGATGC
ATCAGGCAC, R- CATCTTGCGAAAGGCGGAAC;
NEDD9 F-GCTGCCGAAATGAAGTATAAGAATC,
R-GGTCAGGATGTCTCCCTTGC; KDM7A F-
GTCTGAATTGGTGGAGGTCCC, R- ATCTTCTC
ACCCCAGAGGACA; CCDC80 F-GGATCTGTGGCG
GTACTCTG, R-GTGTAATCCAATGGTGGCTCA;
IL11 F- ATGAACTGTGTTTGCCGCCT, R-
TCAGCTGGGAATTTGTCCCTC; STX5 F- AGTC
TTTGGTCGGGTTTCGG, R- CGCATAACCTCGGA
CTCCC. B2M F-ATGAGTATGCCTGCCGTGTG,
R-GGCATCTTCAAACCTCCATG; GAPDH F-
ATGGGGAAGGTGAAGGTCG, R- GGGGTCAT
TGATGGCAACAATA; HRPT1 F-TGACACTGGCAA
AACAATGCA, R-GGTCCTTTTCACCAGCAAGCT
and ACTB F- CATGTACGTTGCTATCCAGGC,
R-CTCCTTAATGTCACGCACGAT.
Signature analysis
Analysis of the SOX4-dependent TGF- target genes was
performed using the online GOBO-software (29).
Statistical analysis
Data are represented as mean ± SD of at least three in-
dependent experiments. Differences were analyzed by un-
paired two-tailed t-test between two groups and by two-way
ANOVA for differences between more than two groups.
RESULTS
SMAD3 is a novel SOX4 interaction partner
In order to achieve target selectivity and control of cell-
type specificity, SOX transcription factors interact with dis-
tinct DNA-binding factors (30). To identify SOX4 tran-
scription factors partners, we performed an unbiased in-
teraction screen by utilizing a TF–TF interaction array.
This technique enables the generation a global view of
transcription factor interaction-networks (Supplementary
Figure S1A). Since we and others have previously iden-
tified a role for SOX4 in regulating mammary epithelial
homeostasis, MCF-7 cells, a well characterized breast can-
cer cell line, were utilized in this assay (5,10,31). Analy-
sis of co-immunoprecipitated probes identified the specific
association between Sox4 and the TGF- pathway effec-
tor transcription factor SMAD3 (Figure 1A and Supple-
mentary Figure S1B). As it has been previously shown that
SOX4 is itself a TGF- target gene (5,10,17), interaction be-
tween SOX4 and SMAD3 indicates that SOX4 is not only
a transcriptional target of TGF- but may also be a rele-
vant player in directly regulatingTGF-mediated transcrip-
tional responses.
While the TF-TF array cannot distinguish between
SMAD family members, SMAD3 was initially chosen to
pursue as an interaction partner since it is a TGF- re-
ceptor SMAD, and directly binds DNA. In order to vali-
date this interaction, co-immunoprecipitation analysis was
performed utilizing HEK293T cells ectopically expressing
HA-SOX4 and FLAG-SMAD3, demonstrating the asso-
ciation between these two proteins (Figure 1B). The as-
sociation between SOX4 and SMAD3 was also observed
in cell lysates treated with ethidium bromide, which dis-
rupts DNA-mediated interactions (32), indicating that a
protein-protein interaction and not DNA-mediated inter-
action is likely responsible for the co-immunoprecipitation
of SMAD3 (Figure 1B).
To evaluate endogenous interaction between SOX4 and
SMAD3, in situ proximity ligation analysis (PLA) was uti-
lized, which selectively enables the detection of proteins that
are in very close proximity. For the PLA analysis, we uti-
lized human mammary epithelial cells (HMLEs), that we
have previously demonstrated to express SOX4 and respond
to TGF- by increasing SOX4 at the transcript level (10).
PLA-analysis using SOX4 and SMAD3 specific antibodies
inHMLE cells demonstrated that nuclear PLA-signal could
be detected only upon incubation with both antibodies,
whereas only unspecific signal was observed in single anti-
body control conditions (Figure 1C). Increased PLA-signal
was observed upon TGF- treatment, indicating that acti-
vation of TGF- signaling pathway is important for SOX4-
SMAD3 association. Moreover, although to a lesser extent,
interaction between SOX4 and SMAD3 was observed in
untreated conditions, suggesting autocrine TGF- signal-
ing in these cells. In line with these observations, both SOX4
and SMAD3baseline protein expression has been found de-
creased upon the incubation with SB431542, a specific In-
hibitor of TGF- receptor kinase (7,33). Taken together,
these findings identify a novel interaction between SOX4
and SMAD3.
SOX4 interacts with SMAD3 in a phosphorylation indepen-
dent manner
To further define both the specificity and functional pro-
tein domains mediating the interaction between SOX4
and the SMAD3, interaction with other members of the
SMAD-family of transcription factors was evaluated. To
this end, co-immunoprecipitation was performed using
Sox4 and SMAD1-7. SOX4 was found to strongly asso-
ciates with the receptor-SMADs of the TGF- signaling
pathway, SMAD2 and SMAD3, but not with SMAD4 (Fig-
ure 1D). In contrast to SMAD3, SMAD2 does not directly
bind to DNA (34). No interaction was observed with the
BMP-signaling associated receptor-SMADs, SMAD1 and
SMAD5 or with the inhibitory SMAD7 and a weak inter-
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Figure 1. SOX4 associates with the MH2-domain of SMAD3 independent of receptor-mediated phosphorylation. (A) MCF7 cells were transfected with
FLAG-Sox4 or an empty vector control. Biotin-labeled transcription factor binding probes were added to the cell lysate after which Sox4 was immunopre-
cipitated using a FLAG- antibody. Subsequently, specifically bound probes were hybridized to the TF-TF array and visualized using streptavidin antibodies.
(B) HEK293T cells were transfectedwithHA-Sox4 andFLAG-SMAD3. Lysates were treatedwith 25g/mlEtBr for 20min after which Sox4was immuno-
precipitated and immunoblots were probed forHA andFLAG.Results are representative of at least three independent experiments. (C) The SOX4-SMAD3
interaction was analyzed by PLA. HMLE cells were treated with 2.5 ng/ml TGF- overnight or left untreated. Left panel: Punctate staining indicates the
specific interaction between the two proteins and DAPI was used to co-stain the nucleus. Right panel: Quantification of punctate staining relative to anti-
SOX4 condition (negative control). Results are representative of three independent experiments. (D) HEK293T cells were transfected with HA-Sox4 and
FLAG-SMAD1–7. Sox4 was immunoprecipitated from cell lysates and co-immunoprecipitation of SMAD proteins was assessed by immunoblot for HA
and FLAG-epitope antibodies. Results are representative of at least three independent experiments. (E) Top panel: Schematic representation of SMAD3
protein. Bottom panel: HA-Sox4 was immunoprecipitated from HEK293T cells co-transfected with full-length SMAD3 (1–425aa), the N-terminal (1–
145aa) or C-terminal SMAD3 regions (146-425aa). Results are representative of at least three independent experiments. (F) HEK293 cells were transfected
with HA-Sox4 and Flag-SMAD3 wild-type (WT) or phosphorylation-defective SMAD3 S3A. Sox4 was immunoprecipitated from cell lysates and protein
expression was assessed by immunoblot using anti-HA and Flag antibodies. Images are representative of three independent experiments.
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action was found with SMAD6 (Figure 1D). These obser-
vations indicate that SOX4 is specifically associatedwith the
effectors of TGF- signaling pathway.
The domain structure of SMAD-proteins is well-defined,
consisting of the DNA-binding Mad-homology 1 and 2
domains (MH1 and MH2), which are involved in DNA-
binding and protein–protein association, respectively (34).
Co-immunoprecipitation analysis demonstrated that SOX4
specifically associated with a C-terminal region of SMAD3
comprising the MH2 domain and linker region, whereas
no interaction was observed with the MH1 domain (Fig-
ure 1E). Since activated SMAD3 requires phosphorylation
at C-terminal serines, we next investigated whether the in-
teraction between SOX4 and SMAD3 may be regulated by
SMAD3 phosphorylation. The interaction between Sox4
and SMAD3 was also observed when these serine-residues
were mutated to alanine (Figure 1F), indicating that this
protein-protein interaction is independent of phosphoryla-
tion at these sites. Taken together, these findings map the
interaction between SOX4 and SMAD3 and indicate that
the association does not rely directly on phosphorylation of
the canonical-phosphorylation sites.
Genome-wide co-occupancy of SOX4 and SMAD3 in breast
cell lines is context dependent
To further evaluate the association between SOX4 and
SMAD3 at the DNA-level on a genome-wide scale
we performed chromatin-immunoprecipitation-sequencing
(ChIP-seq) for both factors in TGF- treated HMLE
cells. These cells were chosen because TGF- has been
shown to promote pro-oncogenic responses including EMT
(10,35,36). We successfully identified both SOX4 and
SMAD3 bound loci and binding of both factors can be
observed on the selected examples for TGF-/SOX4 tar-
get genes VCAN, MMP2 and PDGFBR, and binding of
both transcription factors occurs in the same region, as
indicated by overlapping peaks (Figure 2A). While SOX4
and SMAD3 co-occupancy was observed in the absence
of exogenous TGF-, it increased markedly upon TGF-
treatment (Figure 2B). These findings suggest that the tran-
scriptional response to TGF- may be driven by increased
recruitment of both SOX4 and SMAD3, rather than by
de novo recruitment or a global redistribution. The base-
line binding may be the result of autocrine activation of
TGF- signaling, which has previously been demonstrated
to occur in mammary epithelial cells (37). Analysis of the
genomic distribution of SOX4 and SMAD3 in annotated
regions demonstrated that binding of both factors is en-
riched at promoter regions compared to the contribution
of promoter regions in the total genome (Figure 2C). To
assess whether co-binding occurs on a genome-wide scale
we overlapped SOX4 and SMAD3 bound loci, and found
that the majority of SOX4 bound sites are co-occupied by
SMAD3 (Figure 2D), The co-occupied sites, which occur at
bothTSS-proximal andmore distal regions, are enriched for
markers associated with active/open chromatin (H3K27ac,
H3K4me3 and POL2) (Supplementary Figure S2A-B). This
observation is consistentwith the notion that SMAD3bind-
ing is directed by the epigenome (13). Approximately, 30%
of sites were exclusively bound by SOX4, and these sites
were enriched at TSS-proximal regions, including 5′UTR,
TSS and promoter region, and characterized by high-levels
of the TSS-associated histone-mark, H3K4me3 (Figure 2D
and Supplementary Figure S2A-B). Since the number of
SMAD3 bound loci exceeds the number of SOX4 bound
sites, a larger proportion of SMAD3 binding appears to be
SOX4-independent. These SMAD3-only sites aremostly lo-
cated at TSS-distal sites and are also characterized bymark-
ers of active regions in the genome (Supplementary Figure
S2A and B).
The large degree of overlap between SOX4 and SMAD3
is also highlighted by co-occupancy analysis of SOX4 and
SMAD3 bound sites, which identified reciprocal and cen-
tral enrichment of the binding of both factors (Figure 2E).
Consistent with cooperative binding, motif enrichment and
motif distribution analysis showed the co-occurrence of the
consensus SMAD3 DNA-binding motif in SOX4 bound
sites and vice versa (Figure 2F–G). When centered around
the SOX4-consensus binding site within the co-occupied
sites, central enrichment of the SMAD3-motif was not ev-
ident (Supplementary Figure S2C). Moreover, spaced mo-
tif analysis failed to determine a defined mode of site selec-
tion, suggesting that there is freedom in the co-binding of
transcriptional complexes comprising SOX4 and SMAD3.
Moreover, the central and reciprocal enrichment of these
DNA-binding motifs could only be observed at co-bound
sites, with exclusive enrichment of SOX4 and SMAD3 mo-
tifs at SOX4-only and SMAD3-only sites, respectively (Sup-
plementary Figure S2D). Taken together, these findings
demonstrate co-occupancy of SOX4 and SMAD3 on a
genome-wide level, which is in part dependent on the co-
occurrence of consensus DNA-binding motifs and relies on
the activity of the TGF- pathway.
Since the effect of TGF- is pleiotropic and can promote
dichotomous cellular responses, we assessed the potential
role of the SOX4-SMAD3 interaction in two additional
breast cancer lines: MDA-MB-231 and HCC1954 cells, in
which TGF- elicits contrasting responses. In HCC1954
cells, TGF- inhibits cell proliferation and stem-like traits,
whereas in MDA-MB-231 cells the response induces prolif-
eration, breast cancer initiating cell-like characteristics and
metastasis (22). ChIP-seq analysis performed in these lines
demonstrated that similar to HMLE cells, SOX4 bound
sites were co-occupied by SMAD3 on a genome-wide level
in bothMDA-MB-231 andHCC1954 cells (Supplementary
Figure S3A). This co-occupancy was apparent when the
consensus peaks obtained from two replicate ChIP-seq ex-
periments were analyzed (Supplementary Figure S3A, right
panel). In concordance with the HMLE data, a significant
portion of the SMAD3 sites were observed to be SOX4-
independent (Supplementary Figure S3A). Additionally,
co-occupancy analysis demonstrated that the SOX4 signal
is also centrally enriched at SMAD3 bound sites in both
MDA-MB-231 and HCC1954 cells (Supplementary Figure
S3B). Similarly, in these cells both SOX4 and SMAD3 bind-
ing was found to be induced by TGF- (Supplementary
Figure S3C). Interestingly, comparison of SOX4-SMAD3
co-bound sites in all cell lines demonstrated only a small
degree of overlap (Supplementary Figure S3D). Analysis
of H3K27Ac ChIP-seq data from HMLE, MDA-MB-231
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Figure 2. SOX4 and SMAD3 binding sites overlap on a genome-wide level. (A) Visualization of SOX4 and SMAD3 ChIP-seq profiles contained within the
genomic region surrounding the VCAN,MMP2 and PDGFBR loci. (B) Average profile plot of SOX4 and SMAD3 signals in TGF- treated and untreated
HMLE cells. (C) Genomic-distribution of SOX4 and SMAD3 binding sites in annotated regions compared to background genomic sites. (D) Venn-diagram
showing the overlap of SOX4 and SMAD3binding sites in TGF- treatedHMLEcells (overnight 2.5 ng/ml). (E) Occupancymaps representing the intensity
of SOX4 and SMAD3 binding in a 5kb regions surrounding the peak centers. (F) Motif-distribution analysis of SMAD3 and SOX4 motifs in co-bound
genomic loci. (G) Motif enrichment analysis of SOX4 and SMAD3 bound sites using both de novo and known-motif discovery. miRNA: microRNA; TSS:
transcription start site; 5′UTR: five prime untranslated region; 3′UTR: three prime untranslated region; ncRNA: non-coding RNA.
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and HCC1954 cells suggest that this context-dependent
binding SOX4-SMAD3 complexes is dictated by the cell-
intrinsic chromatin landscape which is defined by this ac-
tive chromatin mark (Supplementary Figure S3E). Taken
together, these findings demonstrate that co-occupancy be-
tween SOX4 and SMAD3 can occur in a wide variety of
breast (cancer) cell lines but this has distinct context-specific
roles, similar to the contextual role for TGF- described in
breast cancer.
Identification of SOX4-dependent TGF- target genes
Since we observed extensive co-binding of SOX4 and
SMAD3, we investigated to what degree the transcriptional
response to TGF- is SOX4-dependent. To this end, we
depleted SOX4 in HMLE cells, which as discussed above,
are non-tumorigenic mammary epithelial cells that upon
exposure to TGF- undergo EMT (5,10,31). Two inde-
pendent shRNA constructs targeting human SOX4 were
used and considering the efficiency of both shRNAs, fur-
ther experiments were performed using shSOX4 1 (Supple-
mentary Figure S4A). Subsequently, the global transcrip-
tional response to TGF- using RNA-sequencing (RNA-
seq) was determined. Analysis of the RNA-seq data showed
167 genes differentially regulated after 16 h of TGF- treat-
ment in the SOX4-depleted HMLE cells compared to con-
trol cells (Supplementary Figure S4B). For the majority
of the SOX4-dependent TGF- target genes, depletion of
SOX4was found to decrease the TGF-mediated induction
of positively regulated target genes (64%). Within the group
of SOX4-dependent TGF- target genes, 84 were found to
be co-bound by SOX4 and SMAD3 in HMLE cells (Fig-
ure 3A), suggesting that these could be directly regulated
through cooperative binding of both factors. Consistent
with the role of SOX4 as a transcriptional activator, the ma-
jority of SOX4-SMAD3 co-bound and SOX4-dependent
TGF- target genes (84 genes) were found to be positively
regulated by TGF- in control cells and reduced upon
SOX4 depletion (73%) (Figure 3A). Gene-ontology enrich-
ment analysis of this co-bound SOX4-dependent TGF-
signature gene-set identified significant association with cel-
lular processes connected to metastasis, including extracel-
lular matrix remodeling, blood vessel development, cell-
adhesion and cell-migration (Figure 3B). In order to val-
idate these targets, we performed quantitative real-time
PCR (qRT-PCR) on SOX4 knockdown and control (SCR)
HMLE cells treated with TGF- for 16 h (Supplemen-
tary Figure S4C). To ensure that results were not depen-
dent on the effect of either TGF- treatment or SOX4-
knockdown on the expression of the housekeeping genes,
we analyzed the expression of four different housekeep-
ing genes in all technical and biological replicates (Supple-
mentary Figure S5A). Results showed no significant vari-
ations within conditions for any of the four housekeep-
ing genes, thereby we further performed our analysis us-
ing 2m. For all the selected SOX4-SMAD3 co-bound and
SOX4-dependent TGF- target genes, depletion of SOX4
resulted in the suppression of TGF--mediated upregula-
tion of such targets, whereas no significant alteration in
gene expression was observed of SOX4-independent TGF-
-regulated genes in SOX4-depleted HMLE cells (Figure
3C). Furthermore, the functional importance of SOX4-
SMAD3 interaction was confirmed by ChIP-qPCR, where
SOX4 knockdown impaired SMAD3-binding to SOX4-
SMAD3 co-bound genes, whereas SMAD3 only targets
were unaffected by SOX4 depletion (Supplementary Figure
S5B). Taken together, our data supports a role for SOX4 in
mediating TGF-/SMADs transcriptional upregulation of
genes involved in tumorigenesis.
SOX4-dependent TGF- target genes correlate with poor-
prognosis
TGF- pathway activity is associated with poor prognosis
in only a subset of breast cancer patients of the claudinlow
subtype. This is consistent with, TGF-’s in vitro and in vivo
pro-tumorigenic roles in claudinlow cells (22,38,39). To eval-
uate whether the SOX4-dependent and -independent TGF-
 gene expression signatures were associated with patient
survival in claudinlow tumors, gene expression data from the
METABRIC cohort of breast cancer patients was stratified
according to similarity to each of the signatures. Kaplan–
Meier analysis of breast tumors with the 25% extreme high
and low correlation values with SOX4-dependent TGF-
gene expression signature (84 genes) demonstrated a signif-
icant correlation with diminished disease-specific survival
(DSS) in claudinlow tumors (Figure 4A; left panel). In con-
trast, analysis of the total TGF- signature devoid of SOX4-
SMAD3 co-bound and SOX4-dependent TGF- target
genes showed little-to-no association with clinical outcome
(Figure 4A; right panel). This, suggests that SOX4may redi-
rect TGF- cellular response toward a pro-malignant clin-
ical outcome, where SOX4-dependent transcriptional tar-
gets play an important role in TGF--mediated tumor pro-
gression. In agreement with the context dependent nature
of the TGF- response, no association with survival was
observed in luminal A, luminal B, HER2 and basal-like
tumor subtypes for both signatures, with the exception of
normal-like tumor subtype (Supplementary Figure S6A).
Since SOX4 modulates a TGF- gene transcriptional net-
work enriched in genes associated with cell migration and
that are associated with poor-prognosis in claudinlow breast
cancer patients, we asked whether SOX4 is required for
the TGF- mediated induction of pro-migratory effects in
the claudinlow MDA-MB-231 cell line. To this end, we per-
formed transwell assays utilizing SOX4-depleted and con-
trol MDA-MB-231 cells (Supplementary Figure S6B) ex-
pressing a control vector or a vector containing the con-
stitutively active TGF- receptor. SOX4 depletion signifi-
cantly reduced migration of highly metastatic MDA-MB-
231 breast cancer cells ectopically expressing the constitu-
tively active TGF- receptor (Figure 4B and C). In addi-
tion, SOX4-knockdown also affected migration in control
cells, suggesting that SOX4 affects autocrine TGF- signal-
ing in these cells. Taken together these findings demonstrate
that the core-SOX4 dependent TGF- signature derived
from combined gene expression profiling and ChIP-seq
analysis is associated with metastasis-associated processes
and correlates with poor-prognosis in claudinlow breast tu-
mors.
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Figure 3. Identification of SOX4-dependent TGF- target genes. (A) Heatmap of SOX4-SMAD3 co-bound and SOX4-dependent TGF- target genes core
identified by RNA-seq. HMLE cells transduced with scrambled control and SOX4 targeting shRNA constructs were treated with TGF- (2.5 ng/ml) for
16 h after which RNA was isolated and analyzed by RNA-seq. Samples are displayed as biological replicates (1 and 2). (B) Gene-ontology analysis using
metascape (http://metascape.org) of SOX4-SMAD3 co-bound and SOX4–dependent TGF- target genes. Significant GO-term clusters are visualized (P<
0.05). (C) qRT-PCR results showing the effect of TGF- (16 h) on expression of SOX4-dependent and independent TGF- target genes. Data represented
as mean ± SD, normalized for 2m (N = 3).
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Figure 4. SOX4-dependent TGF- target genes correlate with poor-prognosis and invasiveness in breast cancer. (A) Kaplan–Meier estimates of disease-
specific survival (DSS) for top (red) and low (blue) quartiles of SOX4-dependent TGF- signature or TGF- signatureminus SOX4-SMAD3 co-bound and
SOX4-dependent TGF- target gene-set in claudinlow breast tumors subtype (B) Quantification of transwell migration of MDA-MB-231 cells transduced
with empty vector (EV) or the constitutively active TGF- receptor (TGFBR-CA) and scrambled control or SOX4 knockdown shRNA constructs. The
number of cells present in the lower well was quantified after overnight incubation. Data was quantified relative to EV-scrambled control MDA-MB-231
cells and is represented asmean± SDof three independent experiments. (C) Representative images of transwell assay stained forDAPI to visualizemigrated
MDA-MB-231 cells.
DISCUSSION
Although SOX4 is overexpressed in a large number of hu-
man cancers, the cellular responses elicited by this tran-
scription factor are highly divergent, thus SOX4 can act as
a tumor-suppressor or pro-oncogenic factor depending on
the cell-type and context (2). In agreement with a highly
context specific function, only a minor degree of overlap
has been observed in SOX4 target genes between distinct
cancers (10). These observations suggest that cell-type spe-
cific factors, such as the epigenome and co-factors shape the
transcriptional network of SOX4. However, the contextual
effects induced by SOX4 remain poorly defined. Here, we
aim to identify the molecular mechanisms determining the
cell context-specific transcriptional output and target gene
selection to better understand SOX4-driven tumorigenesis
and identify therapeutic avenues that specifically disrupt its
pro-oncogenic function.
Cooperative binding is relatively common in the SOX-
family of transcription factors as is exemplified by the in-
teraction between SOX2 and OCT-4, which results in the
regulation of pluripotency genes such as NANOG (30,40).
Here, we identified a novel interaction between SOX4 and
the TGF- effector transcription factor SMAD3 and subse-
9588 Nucleic Acids Research, 2018, Vol. 46, No. 18
quently identified SOX4 as a mediator of the pro-oncogenic
effects of the TGF- signaling pathway. Many of the previ-
ously described SMAD3 co-factors are also transcriptional
targets of the TGF- signaling pathway thus forming a
feedback loop that regulate TGF-’s transcriptional net-
work (11). In a similarmanner, transcriptional regulation of
SOX4 by TGF- in breast cancer cells may act to promote
cooperative gene regulation between SOX4 and SMAD3.
In this respect is it possible that cooperative transcriptional
regulation between these two factors also contributes to
TGF- responses in additional cell-types in which SOX4 is
induced by TGF- including glioma, pituitary-cells and T-
cells (8,9,14).
Interestingly, other SOX-family members have also been
described to interact with SMAD3 including SOX2 in lung
epithelial cells and SOX9 in chondrocytes, suggesting that
SMAD and SOX transcription factors have co-evolved to
cooperatively regulate target genes in response to TGF-
(41,42). Depletion of SOX4 affected a specific subset of
TGF- transcriptional targets, suggesting that in HMLE
cells the response to TGF- does not solely rely on the
expression of SOX4 and is likely controlled by additional
(transcription) factors. This is in line with observations
showing that C/EBP, FOXO and AP1, control distinct
subsets of TGF- target genes through cooperative bind-
ing with SMAD3 (43,44). Interestingly, we observed that
SOX4-SMAD3 co-bound sites were highly cell-type spe-
cific, as indicated by the minor degree of overlap between
co-bound sites in HMLE, MDA-MB-231 and HCC1954
cells, suggesting that additional cell-type specific factors in
concert with the epigenome determine binding and target
gene activation.
SOX4-dependent TGF- target genes were observed to
be enriched for processes such as cell migration and ex-
tracellular matrix organization. Interestingly, this subset of
SOX4 dependent TGF- target genes was also enriched for
gene ontology terms related to cardiovascular system devel-
opment matching phenotype connected to SOX4 depletion
in knockout mice (45). This suggests that SOX4-mediated
modulation of the TGF- pathway may also contribute to
the phenotypic effects observed upon depletion of SOX4 in
vitro and in vivo.
In breast cancer, the SOX4-dependent TGF- signature
was found to be correlated with poor-disease outcome in
the claudinlow subtype. The majority of claudinlow breast
cancers are characterized by low expression levels of lumi-
nal differentiation markers and high levels of EMT mark-
ers (28). In line with these observations, SOX4 expression
has been shown to contribute to TGF--mediated EMT
in human mammary cells (5,10,31), suggesting that SOX4-
mediated reduction of disease-specific survival (DSS) is
achieved by regulating genes involved in the acquisition of
mesenchymal traits. Differences in outcome in breast can-
cer have been linked to cell-type-dependent co-factors and
enrichment of stem cell-like traits (22). Taken together, our
results suggest a novel role for SOX4 in the TGF- signal-
ing pathway by acting as a SMAD3 co-factor and coopera-
tively regulating pro-metastatic genes contributing to poor
outcome in breast cancer patients. Lack of correlation with
disease outcome and SOX4-dependent TGF- signature in
other breast cancer subtypes is possibly due to differences
in cell-type specific epigenomes and SOX4 co-factors.
Consistent with a pro-metastatic role in claudinlow tu-
mors, we observed that SOX4 depletion affects MDA-MB-
231 migration in the presence of TGF-. The transcrip-
tional response to TGF- differs greatly between MDA-
MB-231 and HCC1954 cells, resulting in contrasting ef-
fects on the TGF- mediated induction of tumor-initiating
cells (22). Accordingly, we observe that SOX4-SMAD3 co-
bound sites are almost completely distinct between these
two cell lines, although it remains to be determined how
this affects SOX4-dependent TGF- target gene regulation
and functional effects. In line with these observations, it
has been demonstrated that in pancreatic ductal adeno-
carcinoma (PDA), SOX4 can control either pro-apoptotic
or pro-metastatic gene expression networks downstream of
TGF-, dependent on the cell-type dependent expression
of SMAD4 and KLF5 (18). In our dataset, the SOX4-
dependent TGF- signature does not appear to correlate
with genes associated with apoptosis and SOX4-depedent
induction of pro-metastatic TGF- target genes in breast
cancer appears to be independent ofKLF5 expression (Sup-
plementary Figure S6C), suggesting that regulation of these
gene-sets is dependent on distinct transcription factors and
a permissive epigenome.
Taken together, our findings strongly support that SOX4
is not only a TGF- target but also a critical effector of the
TGF- signaling pathway in breast epithelial cells. These
results also highlight the importance of co-factors in de-
termining both SOX4 and SMAD3 gene networks on a
genome-wide level. Importantly, our finding that the SOX4-
dependent TGF- target genes are associated with poor-
prognosis in claudinlow tumors indicates that targeting of
the interaction between SOX4 and SMAD3 may have ther-
apeutic merit in this subtype.
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